Labcorp stock gains on report-backed growth and cash flow

Labcorp stock reflects a business with $13.0 billion in 2024 revenue, $1.3 billion in operating income, and $1.0 billion in free cash flow. The company also reported 2024 adjusted EPS of $14.57 and returned $679 million to shareholders.

Labcorp (ISIN US50540R4092) is framed by 2024 numbers that give investors a clean baseline: $13.0 billion in revenue, $1.3 billion in operating income, and $1.0 billion in free cash flow. Those figures come from the company’s latest annual reporting and show a business that remained cash generative while scaling a large diagnostics and drug-development platform.

Revenue reached $13.0 billion

Labcorp reported 2024 revenue of $13.0 billion, up from $12.5 billion in 2023, which puts year-over-year growth at roughly 4%. The company also said operating income was $1.3 billion in 2024, compared with $1.2 billion a year earlier, a second sign that the top line translated into profit rather than only volume. Adjusted EPS reached $14.57 for 2024, giving the stock a profits-based reference point rather than a purely narrative one.

Cash flow stayed strong

Free cash flow was $1.0 billion in 2024, while Labcorp reported $679 million of capital returned to shareholders in the same year. That combination matters because it shows the company was able to fund operations, invest, and still send cash back to owners. The balance-sheet picture also remained manageable, with net debt of about $4.2 billion at year-end 2024, according to the annual report.

For the stock, the key comparison is not only revenue growth but conversion: more than $1 billion in free cash flow from $13.0 billion in sales is a useful marker for a mature healthcare services group. It suggests that earnings quality and cash generation remain central to the equity story.

Margin is the tell

Labcorp said operating income of $1.3 billion in 2024 came on revenue of $13.0 billion, which implies an operating margin of about 10%. In 2023, operating income of $1.2 billion on $12.5 billion in revenue implied a margin closer to 9.6%, so the direction improved modestly year over year. That is the kind of move that matters when investors compare diagnostics names on profitability rather than just growth.

The company also reported adjusted EPS of $14.57 for 2024, which can be set against the prior year as a higher earnings base. A stock tied to healthcare testing and drug-development services usually trades on this mix of steady demand, margin discipline, and capital return, not on a single product cycle.

Diagnostics and development

Labcorp’s business is split between diagnostic laboratories and central laboratory services for clinical trials, and that mix gives it multiple operating levers. The 2024 report shows why the market tends to focus on both sides at once: diagnostics provide scale, while drug-development work can add higher-value service revenue when trial activity is healthy.

For investors reading the stock through a fundamental lens, the important point is that the company is not relying on one short-term catalyst. It is using a large recurring testing base, a clinical-development franchise, and cash generation to support the equity case over time.

Labcorp Diagnostics

Labcorp Diagnostics remains the core revenue engine, and that matters because it anchors the company’s operating scale. The annual report shows the group produced $13.0 billion in total revenue in 2024, so even small percentage changes in the diagnostics franchise can move absolute dollars by a meaningful amount.

The product or service line that best captures the stock story is the diagnostics platform itself. It is the unit most closely tied to everyday demand, reimbursement dynamics, and the company’s ability to turn testing volume into cash.

Market level reference

Because no dated quote was available in the research set, the most recent hard market reference in this article is the 2024 operating picture rather than a live trade print. That still leaves a visible valuation frame: $1.0 billion in free cash flow, $1.3 billion in operating income, and $13.0 billion in revenue are the numbers that set the context for any current move in Labcorp stock.

Labcorp at a glance

• Company: Laboratory Corporation of America Holdings
• ISIN: US50540R4092
• Ticker: NYSE: LH
• Trading venue: NYSE
• Sector / Industry: Health Care / Diagnostics & Research
• Index membership: S&P 500